Crispr Therapeutics AG (NASDAQ:CRSP) has received a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $65.03.
A number of analysts have recently commented on the company. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 13th. Zacks Investment Research downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Wednesday, August 8th. Raymond James assumed coverage on Crispr Therapeutics in a research note on Thursday, September 20th. They issued an “underperform” rating on the stock. Finally, Citigroup dropped their price objective on Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating on the stock in a research note on Friday, August 24th.
CRSP opened at $36.56 on Friday. Crispr Therapeutics has a one year low of $16.51 and a one year high of $73.90. The firm has a market capitalization of $2.09 billion, a PE ratio of -21.38 and a beta of 3.70.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC grew its holdings in shares of Crispr Therapeutics by 123.8% in the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after acquiring an additional 1,300 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Crispr Therapeutics by 91.9% in the 1st quarter. Royal Bank of Canada now owns 26,620 shares of the company’s stock worth $1,217,000 after acquiring an additional 12,751 shares during the last quarter. First Mercantile Trust Co. acquired a new position in shares of Crispr Therapeutics in the 2nd quarter worth $141,000. BlackRock Inc. grew its holdings in shares of Crispr Therapeutics by 3.6% in the 1st quarter. BlackRock Inc. now owns 572,218 shares of the company’s stock worth $26,156,000 after acquiring an additional 19,660 shares during the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new position in shares of Crispr Therapeutics in the 2nd quarter worth $322,000. Institutional investors and hedge funds own 39.13% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Further Reading: Why do company’s buyback their stock?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.